Symbols / BIOA $20.73 -1.14%
BIOA Chart
About
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 865.53M |
| Enterprise Value | 473.24M | Income | -75.79M | Sales | 5.92M |
| Book/sh | 7.74 | Cash/sh | 7.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 62 | IPO | — |
| P/E | 1.52 | Forward P/E | -7.99 | PEG | — |
| P/S | 146.28 | P/B | 2.68 | P/C | — |
| EV/EBITDA | -5.29 | EV/Sales | 79.98 | Quick Ratio | 11.69 |
| Current Ratio | 11.87 | Debt/Eq | 2.57 | LT Debt/Eq | — |
| EPS (ttm) | 13.61 | EPS next Y | -2.59 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -17.46% |
| ROE | -25.64% | ROIC | — | Gross Margin | -63.17% |
| Oper. Margin | -11.27% | Profit Margin | 0.00% | Shs Outstand | 41.75M |
| Shs Float | 29.53M | Short Float | 3.68% | Short Ratio | 1.55 |
| Short Interest | — | 52W High | 24.00 | 52W Low | 2.88 |
| Beta | — | Avg Volume | 682.28K | Volume | 20.39K |
| Target Price | $49.25 | Recom | Buy | Prev Close | $20.97 |
| Price | $20.73 | Change | -1.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$49.25
Mean price target
2. Current target
$20.73
Latest analyst target
3. DCF / Fair value
$-17.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.73
Low
$23.00
High
$62.00
Mean
$49.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | main | Citigroup | Buy → Buy | $52 |
| 2026-02-25 | init | Oppenheimer | — → Outperform | $60 |
| 2026-02-18 | up | Jefferies | Hold → Buy | $62 |
| 2026-01-27 | init | Piper Sandler | — → Overweight | $73 |
| 2025-12-08 | up | Morgan Stanley | Underweight → Equal-Weight | $12 |
| 2025-10-29 | main | Citigroup | Buy → Buy | $15 |
| 2025-10-22 | up | Citigroup | Neutral → Buy | $10 |
| 2025-03-24 | main | Citigroup | Neutral → Neutral | $5 |
| 2025-02-28 | init | William Blair | — → Market Perform | — |
| 2024-12-09 | down | Citigroup | Buy → Neutral | $7 |
| 2024-12-09 | down | Jefferies | Buy → Hold | $7 |
- BioArctic (OM:BIOA B) Valuation Check After Recent Share Price Weakness And Leqembi Growth Expectations - Yahoo Finance Sun, 08 Mar 2026 09
- BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup - MarketBeat ue, 10 Mar 2026 15
- Is BioArctic (OM:BIOA B) Still Fairly Priced After Recent Share Price Pullback - simplywall.st Sun, 08 Mar 2026 04
- $BIOA stock is down 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 15
- BioAge Labs (BIOA) Price Target Increased by 10.09% to 30.60 - Nasdaq Wed, 25 Feb 2026 08
- Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan Wed, 21 Jan 2026 08
- Bioage Labs Inc (BIOA) Stock Price Down 5.15% on Jan 16 - GuruFocus Fri, 16 Jan 2026 08
- 2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool Sat, 13 Dec 2025 08
- BioAge Labs (NASDAQ:BIOA) Shares Gap Down - Here's Why - MarketBeat Mon, 02 Mar 2026 18
- $BIOA stock is up 17% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- Citigroup Upgrades BioAge Labs (BIOA) - Nasdaq Wed, 22 Oct 2025 07
- BioAge seeks up to $75M to advance aging-linked metabolic drugs in offering - Stock Titan ue, 20 Jan 2026 08
- Recent uptick might appease BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners after losing 55% over the past year - Yahoo Finance Sun, 23 Nov 2025 08
- Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat Wed, 25 Feb 2026 08
- Insider Sale: Chief Medical Officer of $BIOA Sells 7,433 Shares - Quiver Quantitative ue, 03 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7433 | 150890.0 | — | Sale at price 20.30 per share. | RUBIN PAUL D | Officer | — | 2026-03-02 00:00:00 | D |
| 1 | 7433 | 35470.0 | — | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | RUBIN PAUL D | Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 3542 | 15514.0 | — | Conversion of Exercise of derivative security at price 4.38 per share. | GOLDSTEIN DOV A | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 3 | 7433 | 139369.0 | — | Sale at price 18.75 per share. | RUBIN PAUL D | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 7433 | 35470.0 | — | Conversion of Exercise of derivative security at price 4.11 - 6.57 per share. | RUBIN PAUL D | Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 3541 | 15510.0 | — | Conversion of Exercise of derivative security at price 4.38 per share. | GOLDSTEIN DOV A | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 6 | 3542 | 15514.0 | — | Conversion of Exercise of derivative security at price 4.38 per share. | GOLDSTEIN DOV A | Chief Financial Officer | — | 2026-01-16 00:00:00 | D |
| 7 | 27000 | 531828.0 | — | Sale at price 18.43 - 21.08 per share. | GOLDSTEIN DOV A | Chief Financial Officer | — | 2026-01-13 00:00:00 | D |
| 8 | 233107 | 4223036.0 | — | Sale at price 18.12 per share. | FORTNEY KRISTEN PH.D. | Chief Executive Officer | — | 2026-01-13 00:00:00 | D |
| 9 | 27000 | 226530.0 | — | Conversion of Exercise of derivative security at price 8.39 per share. | GOLDSTEIN DOV A | Chief Financial Officer | — | 2026-01-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -68.40M | -45.81M | -39.38M |
| TotalUnusualItems | -177.00K | -10.09M | 23.00K |
| TotalUnusualItemsExcludingGoodwill | -177.00K | -10.09M | 23.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -71.11M | -63.85M | -39.72M |
| ReconciledDepreciation | 167.00K | 162.00K | 129.00K |
| EBITDA | -68.58M | -55.90M | -39.35M |
| EBIT | -68.74M | -56.06M | -39.48M |
| NetInterestIncome | 7.26M | -5.36M | 224.00K |
| InterestExpense | 2.37M | 7.79M | 241.00K |
| InterestIncome | 9.63M | 2.43M | 465.00K |
| NormalizedIncome | -70.93M | -53.76M | -39.74M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -71.11M | -63.85M | -39.72M |
| TotalExpenses | 78.19M | 48.40M | 39.97M |
| TotalOperatingIncomeAsReported | -78.19M | -48.40M | -39.97M |
| DilutedAverageShares | 10.73M | 20.12M | 1.67M |
| BasicAverageShares | 10.73M | 20.12M | 1.67M |
| DilutedEPS | -6.63 | -3.17 | -23.76 |
| BasicEPS | -6.63 | -3.17 | -23.76 |
| DilutedNIAvailtoComStockholders | -71.11M | -63.85M | -39.72M |
| NetIncomeCommonStockholders | -71.11M | -63.85M | -39.72M |
| NetIncome | -71.11M | -63.85M | -39.72M |
| NetIncomeIncludingNoncontrollingInterests | -71.11M | -63.85M | -39.72M |
| NetIncomeContinuousOperations | -71.11M | -63.85M | -39.72M |
| PretaxIncome | -71.11M | -63.85M | -39.72M |
| OtherIncomeExpense | -177.00K | -10.09M | 23.00K |
| SpecialIncomeCharges | -250.00K | 0.00 | |
| OtherSpecialCharges | 250.00K | ||
| GainOnSaleOfSecurity | 73.00K | -10.09M | 23.00K |
| NetNonOperatingInterestIncomeExpense | 7.26M | -5.36M | 224.00K |
| InterestExpenseNonOperating | 2.37M | 7.79M | 241.00K |
| InterestIncomeNonOperating | 9.63M | 2.43M | 465.00K |
| OperatingIncome | -78.19M | -48.40M | -39.97M |
| OperatingExpense | 78.19M | 48.40M | 39.97M |
| ResearchAndDevelopment | 59.04M | 33.89M | 30.52M |
| SellingGeneralAndAdministration | 19.16M | 14.51M | 9.45M |
| GeneralAndAdministrativeExpense | 19.16M | 14.51M | 9.45M |
| OtherGandA | 19.16M | 14.51M | 9.45M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 35.85M | 34.17M | 34.17M |
| ShareIssued | 35.85M | 34.17M | 34.17M |
| NetDebt | 31.41M | ||
| TotalDebt | 8.70M | 53.25M | 2.47M |
| TangibleBookValue | 323.13M | -173.40M | -112.56M |
| InvestedCapital | 331.63M | -120.34M | -110.14M |
| WorkingCapital | 329.33M | -32.86M | 22.17M |
| NetTangibleAssets | 323.13M | -173.40M | -112.56M |
| CapitalLeaseObligations | 202.00K | 194.00K | 49.00K |
| CommonStockEquity | 323.13M | -173.40M | -112.56M |
| TotalCapitalization | 325.63M | -165.19M | -110.31M |
| TotalEquityGrossMinorityInterest | 323.13M | -173.40M | -112.56M |
| StockholdersEquity | 323.13M | -173.40M | -112.56M |
| GainsLossesNotAffectingRetainedEarnings | 245.00K | 164.00K | 167.00K |
| OtherEquityAdjustments | 245.00K | 164.00K | 167.00K |
| RetainedEarnings | -252.81M | -181.70M | -117.85M |
| AdditionalPaidInCapital | 575.69M | 8.14M | 5.12M |
| CapitalStock | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 35.11M | 199.32M | 140.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.33M | 141.15M | 135.13M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 132.72M | 132.72M |
| DerivativeProductLiabilities | 156.00K | 229.00K | 153.00K |
| NonCurrentDeferredLiabilities | 4.67M | 0.00 | |
| NonCurrentDeferredRevenue | 4.67M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 2.50M | 8.20M | 2.25M |
| LongTermDebt | 2.50M | 8.20M | 2.25M |
| CurrentLiabilities | 27.77M | 58.17M | 5.86M |
| OtherCurrentLiabilities | 417.00K | 1.39M | 24.00K |
| CurrentDeferredLiabilities | 7.83M | 3.31M | 0.00 |
| CurrentDeferredRevenue | 7.83M | 3.31M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 6.20M | 45.05M | 216.00K |
| CurrentCapitalLeaseObligation | 202.00K | 194.00K | 49.00K |
| CurrentDebt | 6.00M | 44.86M | 167.00K |
| OtherCurrentBorrowings | 6.00M | 44.86M | 167.00K |
| PayablesAndAccruedExpenses | 13.33M | 8.41M | 5.62M |
| CurrentAccruedExpenses | 11.33M | 6.55M | 3.36M |
| Payables | 2.00M | 1.87M | 2.26M |
| AccountsPayable | 2.00M | 1.87M | 2.26M |
| TotalAssets | 358.23M | 25.92M | 28.43M |
| TotalNonCurrentAssets | 1.13M | 618.00K | 399.00K |
| OtherNonCurrentAssets | 240.00K | 25.00K | |
| InvestmentsAndAdvances | 100.00K | 100.00K | 0.00 |
| OtherInvestments | 100.00K | 100.00K | 0.00 |
| NetPPE | 791.00K | 518.00K | 374.00K |
| AccumulatedDepreciation | -371.00K | -419.00K | -253.00K |
| GrossPPE | 1.16M | 937.00K | 627.00K |
| ConstructionInProgress | 176.00K | 0.00 | |
| OtherProperties | 869.00K | 561.00K | 322.00K |
| MachineryFurnitureEquipment | 117.00K | 376.00K | 305.00K |
| CurrentAssets | 357.10M | 25.31M | 28.03M |
| OtherCurrentAssets | 2.75M | 349.00K | 386.00K |
| RestrictedCash | 0.00 | 3.31M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 354.35M | 21.64M | 27.64M |
| CashAndCashEquivalents | 354.35M | 21.64M | 27.64M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -51.89M | -37.53M | -36.28M |
| RepaymentOfDebt | -6.00M | -1.00M | 0.00 |
| IssuanceOfDebt | 0.00 | 36.00M | 2.50M |
| IssuanceOfCapitalStock | 391.62M | 0.00 | |
| CapitalExpenditure | -366.00K | -166.00K | -103.00K |
| InterestPaidSupplementalData | 1.42M | 1.16M | 129.00K |
| EndCashPosition | 354.35M | 24.96M | 27.64M |
| BeginningCashPosition | 24.96M | 27.64M | 61.18M |
| EffectOfExchangeRateChanges | 81.00K | 0.00 | 246.00K |
| ChangesInCash | 329.31M | -2.69M | -33.78M |
| FinancingCashFlow | 381.20M | 34.94M | 2.50M |
| CashFlowFromContinuingFinancingActivities | 381.20M | 34.94M | 2.50M |
| NetOtherFinancingCharges | -5.05M | -63.00K | -45.00K |
| ProceedsFromStockOptionExercised | 634.00K | 4.00K | 44.00K |
| NetPreferredStockIssuance | 170.00M | 0.00 | |
| PreferredStockIssuance | 170.00M | 0.00 | |
| NetCommonStockIssuance | 221.62M | 0.00 | |
| CommonStockIssuance | 221.62M | 0.00 | |
| NetIssuancePaymentsOfDebt | -6.00M | 35.00M | 2.50M |
| NetShortTermDebtIssuance | 0.00 | 23.50M | 0.00 |
| ShortTermDebtIssuance | 0.00 | 23.50M | 0.00 |
| NetLongTermDebtIssuance | -6.00M | 11.50M | 2.50M |
| LongTermDebtPayments | -6.00M | -1.00M | 0.00 |
| LongTermDebtIssuance | 0.00 | 12.50M | 2.50M |
| InvestingCashFlow | -366.00K | -266.00K | -103.00K |
| CashFlowFromContinuingInvestingActivities | -366.00K | -266.00K | -103.00K |
| NetInvestmentPurchaseAndSale | 0.00 | -100.00K | 0.00 |
| PurchaseOfInvestment | 0.00 | -100.00K | 0.00 |
| NetPPEPurchaseAndSale | -366.00K | -166.00K | -103.00K |
| PurchaseOfPPE | -366.00K | -166.00K | -103.00K |
| OperatingCashFlow | -51.52M | -37.36M | -36.18M |
| CashFlowFromContinuingOperatingActivities | -51.52M | -37.36M | -36.18M |
| ChangeInWorkingCapital | 11.18M | 6.71M | 795.00K |
| ChangeInOtherWorkingCapital | 9.19M | 3.31M | |
| ChangeInOtherCurrentAssets | -240.00K | 25.00K | 352.00K |
| ChangeInPayablesAndAccruedExpense | 4.63M | 3.33M | 473.00K |
| ChangeInAccruedExpense | 4.63M | 3.73M | -521.00K |
| ChangeInPayable | 6.00K | -393.00K | 994.00K |
| ChangeInAccountPayable | 6.00K | -393.00K | 994.00K |
| ChangeInPrepaidAssets | -2.40M | 37.00K | -30.00K |
| OtherNonCashItems | 1.03M | 6.51M | 100.00K |
| StockBasedCompensation | 6.98M | 3.02M | 2.54M |
| DepreciationAmortizationDepletion | 167.00K | 162.00K | 129.00K |
| DepreciationAndAmortization | 167.00K | 162.00K | 129.00K |
| Depreciation | 167.00K | 162.00K | 129.00K |
| OperatingGainsLosses | 232.00K | 10.09M | -23.00K |
| GainLossOnInvestmentSecurities | -73.00K | 10.09M | -23.00K |
| GainLossOnSaleOfPPE | 55.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -71.11M | -63.85M | -39.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BIOA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|